• Separating Growth Arrest from Cell Death In Vitro

  2026-09-12

  Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different components of anticancer drug response. By considering proliferative arrest, cell killing, and response timing as related but distinct measurements, the work provides a more interpretable framework for in vitro oncology experiments.

• Recombinant Mouse IFN-γ in MASH-HCC Assays

  2026-09-11

  Recombinant Mouse IFN-γ provides a defined, activity-validated stimulus for testing whether metabolically stressed tumor cells can recover MHC-I antigen presentation. This guide converts the bile acid–NLRC5 findings in MASH-HCC into practical dose-response, co-culture, macrophage, and T-cell workflows.

• KR-12: Applied Workflows for Antimicrobial Research

  2026-09-11

  KR-12 converts a minimal LL-37 fragment into a practical tool for membrane, biofilm, LPS, and host-response assays. This workflow-focused guide explains how to prepare the TFA salt, select informative endpoints, compare planktonic and biofilm activity, and troubleshoot concentration, matrix, and cytotoxicity effects.

• ATP Strategy for PXDN-Driven Glioblastoma Research

  2026-09-10

  A mechanistic and translational framework for using ATP abundance to strengthen PXDN–LDHA studies in glioblastoma, with practical guidance for cellular ATP quantification, tissue workflows, and causal metabolic validation.

• D-N-Acetylgalactosamine: Workflow and QC Guide

  2026-09-10

  D-N-Acetylgalactosamine (SKU B7904) provides a high-purity, water- and DMSO-soluble reagent for controlled analysis of glycoprotein constituents and glycosylation-related workflows. It is not appropriate for ethanol-based preparation or long-term storage of working solutions, and the guidance below is dossier-based because no directly matched paper evidence was supplied.

• 2X Taq PCR Master Mix for Plant Virus Workflows

  2026-09-09

  Build a practical plant-virus confirmation workflow around direct gel loading, A-tailed amplicons, and disciplined controls. The approach complements image-based sweetpotato virus screening by adding a targeted molecular confirmation step without overstating what either method can prove.

• Ampicillin sodium: Assays, Workflows & Troubleshooting

  2026-09-09

  Build reproducible antibacterial activity assays around Ampicillin sodium, from stock preparation and broth microdilution to resistance-focused interpretation. The workflow also shows how to use reference MIC values, orthogonal readouts, and comparative β-lactam designs without mistaking an in vitro benchmark for a clinical conclusion.

• Anlotinib Hydrochloride: From Assay to Translation

  2026-09-08

  Anlotinib hydrochloride links nanomolar receptor inhibition to measurable endothelial phenotypes and a clinically informative case report. This article presents a translational framework for selecting assays, interpreting pharmacology, and recognizing the limits of preclinical-to-clinical inference.

• Anlotinib: VEGFR2 Inhibition and Tumor Angiogenesis

  2026-09-07

  The reference study established anlotinib as a highly potent, comparatively selective VEGFR2 tyrosine kinase inhibitor whose strongest preclinical effects were directed toward tumor-associated endothelial biology. Its progression from biochemical kinase testing through cellular, ex vivo, and xenograft models provides a useful framework for interpreting anti-angiogenic activity while distinguishing vascular effects from direct tumor-cell cytotoxicity.

• ARL4C, Synoviocyte Proliferation, and RA Progression

  2026-09-07

  This study integrates single-cell and bulk transcriptomic data with cellular perturbation, co-culture, and collagen-induced arthritis experiments to position ARL4C as a regulator of aggressive fibroblast-like synoviocytes and macrophage polarization in rheumatoid arthritis. Its findings connect ARL4C-dependent S-phase progression with PI3K/AKT and MAPK signaling, while suggesting an experimental framework for validating synoviocyte proliferation as a disease-relevant phenotype.

• Tivozanib (AV-951) Assay Workflows

  2026-09-05

  Build more informative VEGFR experiments with Tivozanib (AV-951), from endothelial signaling assays to renal cancer models and combination screens. The workflow separates growth arrest from true cell killing, helping researchers avoid overinterpreting a single viability endpoint.

• Fructus Rubi Glycosides in Androgen-Driven BPH

  2026-09-05

  This study shows that a standardized diterpene glycoside extract from Fructus Rubi reduces androgen-associated prostatic enlargement in cell and rat models. Its innovation is the integration of androgen receptor signaling with the S100A2-mediated TGF-β/Smad axis, providing a mechanistic framework for evaluating a multitarget botanical intervention in benign prostatic hyperplasia.

• Celastrol, Mitochondrial Cholesterol, and Mitophagy

  2026-09-04

  A 2026 Phytomedicine study identifies a CAV-1/SCP2-dependent route by which celastrol redistributes cholesterol into mitochondria, elevates mitochondrial stress, and activates mitophagy in liver cancer. The work connects organelle-specific cholesterol metabolism with tumor suppression and provides a mechanistically focused framework for metabolic and mitophagy studies in liver cancer models.

• EdU Flow Cytometry Assay Kits (Cy5): S-Phase

  2026-09-04

  EdU Flow Cytometry Assay Kits (Cy5) provide denaturation-free detection of DNA synthesis during S phase through copper-catalyzed azide-alkyne cycloaddition (CuAAC). The K1078 workflow supports single-cell proliferation measurements and can be integrated with cell-cycle dyes, antibody panels, genotoxicity studies, and pharmacodynamic experiments.

• Anlotinib Hydrochloride: From Target to Translation

  2026-09-03

  A translational analysis of anlotinib hydrochloride, connecting VEGFR2, PDGFRβ, FGFR1, and ERK biology with functional angiogenesis assays, pharmacokinetic interpretation, competitive positioning, and research-strategy decisions.

8440 records 1/563 page Next 12345 下5页 Last page